SNORD116-25

Across TCGA pan-cancer cohorts, SNORD116-25 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated SNORD116-25 data layer compared with 2 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SNORD116-25 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SNORD116-25 expression acts as an unfavorable survival marker, although some lineages such as TGCT show a favorable association.

LIHC, BRCA, and THCA are the cancer types where SNORD116-25 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.079	0.771	.002	45	view →
BRCA	DFS	Tertile	IV	0.175	0.730	.005	36	view →
THCA	DFS	Tertile	IV	0.126	0.805	.002	27	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	18	view →
TGCT	DFS	Quartile	All	0.957	0.778	.022	18	view →
SKCM	OS	Tertile	II,III,IV	0.289	0.735	.019	9	view →
LUAD	OS	Tertile	III,IV	0.235	0.677	.030	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SNORD116-25–LIHC (OS)

Open the LIHC breakdown →